Engraftment after myeloablative doses of131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma
- 1 June 1998
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 30 (6), 339-346
- https://doi.org/10.1002/(sici)1096-911x(199806)30:6<339::aid-mpo7>3.0.co;2-f
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.Journal of Clinical Oncology, 1998
- First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastomaEuropean Journal Of Cancer, 1995
- Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study.Journal of Clinical Oncology, 1993
- Critical observations on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosisMedical and Pediatric Oncology, 1993
- Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.Journal of Clinical Oncology, 1992
- 131-I-Metaiodobenzylguanidine Treatment in Patients with Refractory Advanced NeuroblastomaAmerican Journal of Clinical Oncology, 1992
- [131I]-Metaiodobenzylguanidine in the treatment of metastatic neuroblastomaCancer Chemotherapy and Pharmacology, 1989
- Treatment of neuroblastoma with 131I‐MIBG: Dosimetric problems and perspectivesMedical and Pediatric Oncology, 1987
- Therapeutic use of 131I‐metaiodobenzylguanidine (MIBG) in neuroblastoma: A phase II study in nine patientsMedical and Pediatric Oncology, 1987
- Treatment of neuroblastoma with metaiodobenzylguanidine: Results and side effectsMedical and Pediatric Oncology, 1987